ORIGINAL ARTICLE |
|
Year : 2021 | Volume
: 7
| Issue : 3 | Page : 75-80 |
|
Study of serum S100P level and its relation to diabetic peripheral neuropathy in patients with type-2 diabetes
Talaat A Aaty1, Mohamed Rizk2, Rehab Elnemr3, Aya Ali1, Reem Fathalla1
1 Diabetes and Metabolism Unit, Department of Internal Medicine, Alexandria University Faculty of Medicine, Alexandria, Egypt 2 Department of Clinical and Chemical Pathology, Alexandria University Faculty of Medicine, Alexandria, Egypt 3 Department of Physical Medicine, Rheumatology and Rehabilitation, Alexandria University Faculty of Medicine, Alexandria, Egypt
Correspondence Address:
MD Reem Fathalla Diabetes and Metabolism Unit, Department of Internal Medicine, Alexandria University Faculty of Medicine, Alexandria Egypt
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ejode.ejode_20_21
|
|
Background S100P, a binder of receptors for advanced-glycation end products, is an established biomarker of many types of cancer. However, data regarding its role in diabetes and diabetic peripheral neuropathy (DPN) are unclear.
Aim The aim of this work was to study the relationship between serum S100P and DPN in patients with type-2 diabetes mellitus (T2DM).
Participants and methods This cross-sectional study included a total of 90 subjects divided into three groups: 30 patients with T2DM complicated with peripheral neuropathy (group A), 30 patients with T2DM without peripheral neuropathy (group B), and 30 subjects as healthy-control group (group C). All patients with T2DM were assessed for peripheral neuropathy using Michigan neuropathy screening instruments and nerve-conduction study was done to diagnose subclinical neuropathy. Serum S100P was assessed by enzyme-linked immunosorbent assay technique.
Results Mean serum S100P levels in group A and group B were significantly lower compared with group C (P<0.001 for both comparisons). However, there was no significant difference in mean serum S100P levels between groups A and B (P=0.394).
Conclusion Serum S100P is significantly low in T2DM with no significant association with DPN.
|
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|